KaloBios Pharmaceuticals, Inc. (KBIO) has moved off its lows on heavy volume over the past two days, recovering since a disappointing Phase 2 Study result in January. It appears to be one of a number of biotech stocks recovering off 52-week lows, including EYES which was an alert from a couple of days ago. The stock trades at less than cash value which is $1.49 per share according to Yahoo Finance. When subtracting debt and current liabilities, the cash value per share is still around $1 and even when subtracting $10 million to account for burn rate since the conclusion of the study, the cash per share is over 70 cents. Per the Yahoo figures seen below, the Enterprise value for the company is negative $20 million at 57 cents, meaning that on top of giving away cash, the business has no value at this price. KBIO appears to be a very cheap stock at 57 cents considering its cash situation is much better than similar stocks rising in value recently.